Omzo vs TMates: Compounded GLP-1 Care Compared
Omzo vs TMates: both provide clinician-reviewed access to compounded semaglutide, but they differ on pricing model, clinician availability, medication options, and regulatory notes. Early verdict: choose Omzo if you want lower starting pricing and access to tirzepatide options; choose TMates if you prefer a flat $199/month price with 24/7 U.S. doctor access and nationwide coverage.
Explore Omzo plans starting at $179
Direct comparison: price model and cost transparency
Price is a primary difference in the Omzo vs TMates comparison. Omzo lists semaglutide starting at $179 and tirzepatide starting at $279 as part of clinician-guided, personalized compounded programs. TMates presents a flat $199/month model that it says remains the same at every dose, with sample bundle pricing shown for multi month commitments.
Why this matters
Omzo uses a starting price model that may vary by medication and plan, while TMates emphasizes a predictable flat monthly fee of $199 at every dose. The sources show Omzo includes clinician-guided compounded programs and the option for prescriptions of branded medications that patients must fill separately, whereas TMates focuses on a direct pay flat fee for compounded semaglutide.
Care model and clinician access
Both platforms use clinician oversight but present different access levels. Omzo connects users with licensed U.S. providers who review plans and determine eligibility. TMates advertises 24/7 access to U.S.-based doctors across all 50 states and regular virtual check ins for ongoing medical oversight.
See TMates with 24/7 U.S. doctor access
Medication options and sourcing
Omzo’s platform highlights a Compounded Medication Program prepared by state licensed sterile compounding pharmacies and notes those compounded drugs are not FDA approved. Omzo also states providers may write prescriptions for branded medications such as Ozempic or Wegovy, but Omzo does not sell, dispense, or ship branded products; patients must fill those prescriptions at a pharmacy of their choice.
TMates offers clinically dosed compounded semaglutide formulated in U.S. facilities and positions its compounded semaglutide as an alternative to branded products with more flexible dosing and lower price points. TMates notes its medications are formulated in U.S. based facilities and provides no branding or dispensing of brand name products.
State coverage and eligibility
TMates claims licensed coverage in all 50 states and notes shipping to most states, subject to medical eligibility. Omzo indicates clinicians determine eligibility and that shipping, pricing, eligibility and state coverage may change, advising people to confirm eligibility, total cost, renewal terms and state availability before enrollment.
Regulatory and safety notes
Both sources include the regulatory reminder that compounded medications are not FDA approved and are not reviewed by the FDA for safety, effectiveness, or quality. Omzo explicitly states compounded medications offered through its providers are produced in FDA registered facilities but are not FDA approved and have not been evaluated by the FDA for safety, efficacy or quality. TMates likewise notes compounded medications are not FDA approved.
Quick comparison table
| Criteria | Omzo | TMates |
|---|---|---|
| Price | Semaglutide starting at $179; tirzepatide starting at $279 | Flat $199/month at every dose; sample multi month bundles shown |
| Clinician access | Clinician guided plans reviewed by licensed U.S. providers | 24/7 access to U.S. based doctors plus virtual check ins |
| Medication types | Compounded semaglutide and tirzepatide; providers may prescribe branded meds for pharmacy fill | Clinically dosed compounded semaglutide formulated in U.S. facilities; limited public detail on tirzepatide |
| State coverage | Eligibility and state availability determined by providers; may change | Licensed coverage in all 50 states; ships to most states subject to medical eligibility |
| Regulatory note | Compounded meds not FDA approved; produced in FDA registered facilities but not FDA evaluated | Compounded meds not FDA approved; formulated in U.S. facilities |
Other practical differences
Omzo emphasizes personalized GLP 1 care and lists fast, discreet delivery with FSA and HSA eligibility noted. It also highlights that Omzo is not a medical practice and that third party networks of U.S. licensed clinicians provide clinical services and determine prescription eligibility. TMates emphasizes a straightforward, flat fee experience, free shipping, cancel anytime terms in some plans, and that it provides actual physician availability rather than messaging only support.
Compare Omzo medication and plan details
Final thoughts on Omzo vs TMates
In the Omzo vs TMates comparison, the most distinctive differences are pricing structure, clinician access hours, range of medication options including tirzepatide, scope of state coverage claims, and both providers note compounded medications are not FDA approved. Choose based only on the specific facts each source supplies.
Start TMates enrollment and pricing details
Start Omzo enrollment and eligibility check
Choose which fits you
Choose Omzo if you prioritize lower starting pricing, access to both compounded semaglutide and tirzepatide options, and clinician reviewed personalized plans, and you will confirm eligibility, total cost, renewal terms and state availability before enrolling. Choose TMates if you prefer a predictable flat $199/month price at every dose, 24/7 access to U.S. based doctors, and licensed coverage across all 50 states subject to medical eligibility.